Literature DB >> 1714785

Human monoclonal antibodies to cytomegalovirus recognize viral epitopes on the surface of virus-infected cells.

Y Larose1, E S Tackaberry, B R Brodeur.   

Abstract

Four human monoclonal antibodies directed against human cytomegalovirus were produced by fusing Sp2/HPT heteromyeloma cells with peripheral blood lymphocytes, after stimulation in vitro for 6 days. The human hybridomas have been maintained in culture for one year and secrete, when cultured in serum-free medium, between 3.1 and 8.1 micrograms/ml of antibodies/10(6) cells/24 hours. HCV-1 and HCV-2 are IgG kappa, while HCV-3 and HCV-4 are IgG3 lambda. The four monoclonal antibodies immunoprecipitate a viral protein of 64 kD. Kinetic studies using indirect immunofluorescence indicate that this antigen appears late in the viral infectious cycle. All four monoclonal antibodies recognize human cytomegalovirus prototype strains AD-169, Davis and Towne, and 14 clinical isolates collected between 1984 and 1987. No reactivity was observed with other human herpesviruses. While no neutralizing activity could be observed with the human monoclonal antibodies, binding assays on unfixed infected cells showed that they recognized viral epitopes located on the cell surface membrane. These hybridomas may be useful for future therapy of immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714785

Source DB:  PubMed          Journal:  Hum Antibodies Hybridomas        ISSN: 0956-960X


  2 in total

1.  Anti-idiotypic mimicry of a neutralizing epitope on the glycoprotein B complex of human cytomegalovirus.

Authors:  E S Tackaberry; J Hamel; Y Larose; B R Brodeur
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

2.  Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection.

Authors:  C Söderberg; S Larsson; S Bergstedt-Lindqvist; E Möller
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.